Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05350722 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Single-dose Preoperative Partial Breast Irradiation in Low-risk Breast Cancer Patients

Study acronym: ABLATIVE-2
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv5
  2. Primary completion date: Mar 2025 to Dec 2027
    • Study sites: 1 to 7
    • Study completion date: Mar 2035 to Dec 2037
    v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 2022 to Aug 24, 2022
    • Site details revised
    v3
  4. Start date: Apr 2022 to Jun 2022v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In this ABLATIVE-2 trial, low-risk breast cancer patients will be treated with MRI-guided single dose preoperative partial breast radiotherapy to assess the rate of pathologic complete response after an interval of six to twelve months between radiotherapy and surgery. Response monitoring will be assessed using MRI and markers in blood and tumor tissue to enable prediction of pathologic response.
Trial Details
NCT Number NCT05350722
Lead Sponsor Amsterdam UMC, location VUmc
Collaborators: Dutch Cancer Society
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms, Pathologic Complete Response
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov